AZD9291

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR T790M Mutation Positive NSCLC

Conditions

EGFR T790M Mutation Positive NSCLC

Trial Timeline

— → —

NCT ID

NCT02451852

About AZD9291

AZD9291 is a pre-clinical stage product being developed by AstraZeneca for EGFR T790M Mutation Positive NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT02451852. Target conditions include EGFR T790M Mutation Positive NSCLC.

What happened to similar drugs?

1 of 7 similar drugs in EGFR T790M Mutation Positive NSCLC were approved

Approved (1) Terminated (1) Active (5)

✅GefitinibAstraZenecaApproved

🔄AZD9291 + MEDI4736AstraZenecaPhase 3

🔄AZD9291 80mg oral each dayAstraZenecaPhase 3

🔄AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mgAstraZenecaPhase 3

🔄Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3

❌ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLYRochePhase 3

🔄Dacomitinib (PF-00299804) + GefitinibPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02451852	Pre-clinical	Completed	—	—	EGFR T790M Mutation Positive NSCLC
NCT02811354	Phase 2	UNKNOWN	Feb 24, 2017	Feb 24, 2020	Carcinoma, Non-Small-Cell Lung
NCT02504346	Phase 2	UNKNOWN	Aug 1, 2015	Jun 1, 2023	Lung Cancer
NCT02442349	Phase 2	Completed	Jun 22, 2015	Nov 28, 2025	Non-Small Cell Lung Cancer
NCT02094261	Phase 2	Completed	May 20, 2014	Nov 7, 2023	Non Small Cell Lung Cancer
NCT02096679	Phase 1	Completed	May 1, 2014	Aug 1, 2014	Healthy Volunteers
NCT01802632	Phase 1/2	Completed	Mar 4, 2013	Dec 13, 2023	Advanced Non Small Cell Lung Cancer

Competing Products

20 competing products in EGFR T790M Mutation Positive NSCLC

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	32
YH32364	Yuhan	Phase 1/2	39
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
ASP8273	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
erlotinib	Astellas Pharma	Phase 1	29
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	27
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	31
ABT-414	AbbVie	Pre-clinical	26
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	29
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	42
AZD9291 + MEDI4736	AstraZeneca	Phase 3	40
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	22
Osimertinib	AstraZeneca	Phase 2	35
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	24
AZD9291 80mg oral each day	AstraZeneca	Phase 3	36
Tremelimumab + Durvalumab	AstraZeneca	Phase 2	31
Osimertinib	AstraZeneca	Phase 2	35
AZD3759 + AZD9291	AstraZeneca	Phase 1	29